Consensus Daxor Corporation

Equities

DXR

US2394671034

End-of-day quote Nasdaq Other stock markets 23:00:00 02/05/2024 BST			5-day change	1st Jan Change
9.8 ^USD	-0.81%		-0.91%	+2.08%

04-16	Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	CI
04-10	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	CI

Evolution of the average Target Price on Daxor Corporation

Price target over the last 5 years

History of analyst recommendation changes

c5e494b2f4a68db6b066c20ecca256e4.v6PtmHDzje5qoU7DnLQ1kchz7el-vfx7zh0E5jtXSxE.-JCG7heFz4Uo8Aqs0vpQwvEsuZsricQitm5bsE4NMVzqk4_xSZTfqFLHFw~f3dea263ca1b60e7492f049d9506b098

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.8 USD

Average target price

23.25 USD

Spread / Average Target

+137.24%

High Price Target

24.5 USD

Spread / Highest target

+150.00%

Low Price Target

22 USD

Spread / Lowest Target

+124.49%

Consensus detail

Consensus revision (last 18 months)

Chiffre d''affaires - Rate of surprise

Company calendar